Skip to main content
Premium Trial:

Request an Annual Quote

Meridian Bioscience Projects Growth in Sales, Income for Fiscal 2011


Meridian Bioscience this week said that it expects net sales for its 2011 fiscal year to be in the range of $165 million to $170 million, representing an increase of between 14 percent and 17 percent over projected fiscal 2010 sales.

For the company's 2010 fiscal year, ending Sept. 30, 2010, the company projects sales at the "low end" of its previous guidance of between $145 million and $153 million.

These results exclude the impact of costs associated with Meridian's acquisition in July of PCR reagent provider Bioline (PCR Insider 7/22/2010).

The company said that it expects fiscal 2011 net income to increase between 15 percent and 20 percent over fiscal 2010, excluding Bioline acquisition costs in fiscal 2010 and the impact of any additional acquisitions the company might complete in fiscal 2011.

CEO John Kraeutler said in a statement that in fiscal 2011, the company expects to "rebound from a very difficult FY 2010, a year in which we experienced a non-existent influenza season, competitive pressure in our C. difficile franchise, and a challenging economy."

In July, the company received clearance from the US Food and Drug Administration for its Illumigene C. difficile molecular amplification assay, which amplifies DNA using loop amplification technology and provides results in less than one hour (PCR Insider 7/15/2010).

William Motto, executive chairman of Meridian, said in a statement this week that FDA clearance of the Illumigene platform provides "the opportunity to build an exciting new molecular-based growth platform that will enhance and expand our diagnostic testing methodologies."

He added that the company expects Bioline to begin contributing to earnings and cash flow during fiscal 2011, but did not provide further details.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.